In the last trading session, 1.37 million shares of the Emergent Biosolutions Inc (NYSE:EBS) were traded, and its beta was 1.20. Most recently the company’s share price was $2.16, and it changed around -$0.14 or -6.09% from the last close, which brings the market valuation of the company to $112.75M. EBS currently trades at a discount to its 52-week high of $13.67, offering almost -532.87% off that amount. The share price’s 52-week low was $1.42, which indicates that the current value has risen by an impressive 34.26% since then. We note from Emergent Biosolutions Inc’s average daily trading volume that its 10-day average is 1.12 million shares, with the 3-month average coming to 3.10 million.
Emergent Biosolutions Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended EBS as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Emergent Biosolutions Inc is expected to report earnings per share of -$0.83 for the current quarter.
Emergent Biosolutions Inc (NYSE:EBS) trade information
Instantly EBS has showed a red trend with a performance of -6.09% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -10.00% year-to-date, but still down -14.96% over the last five days. On the other hand, Emergent Biosolutions Inc (NYSE:EBS) is -36.28% down in the 30-day period. We can see from the shorts that 4.91 million shares have been sold at a short interest cover period of 0.74 day(s).
The consensus price target as assigned by Wall Street analysts is $51.5, which translates to bulls needing to increase their stock price by 95.81% from its current value. Analyst projections state that EBS is forecast to be at a low of $38 and a high of $65.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Emergent Biosolutions Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -36.47 percent over the past six months and at a -124.40% annual growth rate that is well below the industry average of 13.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 73.80% in revenue this quarter, and will report an increase of 40.60% in the next quarter. The year-over-year growth rate is expected to be -2.30%, down from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of $224.5 million in revenue for the current quarter. 1 analysts expect Emergent Biosolutions Inc to make $244.5 million in revenue for the quarter ending Jun 2024. Forecasts for the next quarter put sales growth at 13.10%.
EBS Dividends
Emergent Biosolutions Inc’s next quarterly earnings report is expected to be released around May 07 and May 13.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.89% of Emergent Biosolutions Inc shares, and 79.27% of them are in the hands of institutional investors. The stock currently has a share float of 81.63%. Emergent Biosolutions Inc stock is held by 182 institutions, with Blackrock Inc. being the largest institutional investor. By Jun 29, 2023, it held 17.82% of the shares, which is about 9.23 million shares worth $67.85 million.
State Street Corporation, with 13.11% or 6.79 million shares worth $49.94 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Aug 30, 2023. The former held 4.9 million shares worth $22.99 million, making up 9.46% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 1.44 million shares worth around $10.61 million, which represents about 2.79% of the total shares outstanding.
